FDA issues emergency authorisation for nCoV Real-Time RT-PCR diagnostic panel,a diagnostic test for coronavirus.
The FDA has issued emergency use authorisation (EUA) of a diagnostic test for the novel coronavirus, reported to infect more than 24,000 people and kill over 400 since emerging in China in December 2019.
Developed by the Centers for Disease Control and Prevention (CDC), the 2019-nCoV Real-Time RT-PCR diagnostic panel is a test that has previously been limited only to CDC laboratories.The latest authorisation from the FDA will enable to use of the test at any CDC-qualified lab across the country. The US Government recently declared a public health emergency even though the threat of the coronavirus in the US remains relatively low according to the federal health officials.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)